Trial reportPediatric nephrology (Berlin, Germany)1993
Recurrent nephrotic syndrome after transplantation: early treatment with plasmaphaeresis and cyclophosphamide.
Trial report in Pediatric nephrology (Berlin, Germany), 1993. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Ofatumumab treatment for nephrotic syndrome recurrence after pediatric renal transplantation.Pediatric nephrology (Berlin, Germany) · 2020Article
- Recurrent andFrontiers in immunology · 2019Review
- Recurrence of primary glomerulonephritis: Review of the current evidence.World journal of transplantation · 2017Review
- Primary disease recurrence—effects on paediatric renal transplantation outcomes.Nature reviews. Nephrology · 2015Review
- Case series: CTLA4-IgG1 therapy in minimal change disease and focal segmental glomerulosclerosis.Pediatric nephrology (Berlin, Germany) · 2015Article
- Therapeutic plasma exchange for the treatment of pediatric renal diseases in 2013.Pediatric nephrology (Berlin, Germany) · 2014Review
- Physiopathology of idiopathic nephrotic syndrome: lessons from glucocorticoids and epigenetic perspectives.Pediatric nephrology (Berlin, Germany) · 2012Review
- Benefits and limitations of plasmapheresis in renal diseases: an evidence-based approach.Journal of artificial organs : the official journal of the Japanese Society for Artificial Organs · 2011Review
- Screening for NPHS2 mutations may help predict FSGS recurrence after transplantation.Journal of the American Society of Nephrology : JASN · 2011Article
- Rituximab in refractory nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2010Article
- Disease recurrence in paediatric renal transplantation.Pediatric nephrology (Berlin, Germany) · 2009Review
- Long-term outcome of idiopathic steroid-resistant nephrotic syndrome: a multicenter study.Pediatric nephrology (Berlin, Germany) · 2009Article
- Recurrent glomerulonephritis after renal transplantation: an unsolved problem.Clinical journal of the American Society of Nephrology : CJASN · 2008Review
- Remission of steroid- and CyA-resistant nephrotic syndrome using multiple drug immunosuppression.Pediatric nephrology (Berlin, Germany) · 2007Article
- Recurrence of nephrotic syndrome/focal segmental glomerulosclerosis following renal transplantation in children.Pediatric nephrology (Berlin, Germany) · 2007Review
- Does rituximab treat recurrent focal segmental glomerulosclerosis post-renal transplantation?Pediatric nephrology (Berlin, Germany) · 2007Article
- Recurrence of nephrotic syndrome after renal transplantation: influence of increased immunosuppression.Pediatric nephrology (Berlin, Germany) · 2005Article
- Complete remission of post-transplant FSGS recurrence by long-term plasmapheresis.Pediatric nephrology (Berlin, Germany) · 2005Article
- Early use of plasmapheresis for recurrent post-transplant FSGS.Pediatric nephrology (Berlin, Germany) · 2003Article
- Extrarenal effects on the pathogenesis and relapse of idiopathic nephrotic syndrome in Buffalo/Mna rats.The Journal of clinical investigation · 2002Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Steroid-resistant nephrotic syndrome (NS) with focal glomerulosclerosis (FGS) and its recurrence after transplantation are mainly seen in children. The recurrence rate approximates 30% and the graft loss is about half this. Several therapeutic regimens have been proposed, giving conflicting results. In an attempt to remove a putative circulating factor and inhibit its production by lymphocytes, three patients with biopsy-proven FGS in the native kidney were included in a prospective uncontrolled trial using early plasmaphaeresis followed by substitutive immunoglobulins in association with methylprednisolone pulses and cyclophosphamide instead of azathioprine over a 2-month period. The patients were girls, aged 6.5, 13.3 and 15.8 years, who received a cadaveric transplant; concomitant immunosuppression included prednisone and cyclosporine A. All three patients exhibited early recurrence of the NS and were treated 5-10 days after the onset of proteinuria. Rapid and sustained remission was achieved in all patients within 12-24 days on therapy. One patient experienced a late acute but steroid-sensitive rejection episode; another suffered from septic ankle arthritis as a complication of reinforced immunosuppression. The latter girl had a second late recurrence of proteinuria that was controlled within 7 weeks. With a 18- to 27-month follow-up, all three patients have normal renal function, normal blood pressure and no proteinuria. We conclude that intensive therapy using plasmaphaeresis, steroid pulses and cyclophosphamide over a 2-month period can induce complete remission in children with early recurrence of NS after transplantation.
Indexed as
Identifiers
8439479What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.